MK-2214
/ Merck (MSD)
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
November 25, 2024
A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)
(clinicaltrials.gov)
- P1 | N=48 | Active, not recruiting | Sponsor: Merck Sharp & Dohme LLC | Recruiting ➔ Active, not recruiting
Enrollment closed • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • CSF P-tau
July 25, 2023
A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)
(clinicaltrials.gov)
- P1 | N=48 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Trial completion date: Nov 2024 ➔ May 2025 | Trial primary completion date: Nov 2024 ➔ May 2025
Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • CSF P-tau
September 27, 2022
A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)
(clinicaltrials.gov)
- P1 | N=48 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Not yet recruiting ➔ Recruiting
Enrollment open • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • CSF P-tau
July 20, 2022
A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)
(clinicaltrials.gov)
- P1 | N=48 | Not yet recruiting | Sponsor: Merck Sharp & Dohme LLC
New P1 trial • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • CSF P-tau
1 to 4
Of
4
Go to page
1